Drugs /

bnz-1

Back to Drugs List

Overview

NCI Definition [1]:
A pegylated peptide antagonist that binds to the common gamma chain (gc; IL2RG; CD132) of the signaling receptor for the pro-inflammatory cytokines interleukin (IL)-2, IL-9, and IL-15, with potential immunomodulating and antineoplastic activities. Upon administration, IL-2/9/15 gc receptor inhibitor BNZ-1 specifically targets and binds to the IL binding site on the gc receptor and blocks IL-2, IL-9 and IL-15 binding, thereby inhibiting IL-2-, IL-9-, and IL-15-mediated signaling and downstream pathways. This may inhibit proliferation of tumor cells that are dependent on IL-2/9/15 signaling for their growth. IL-2/9/15 are upregulated in certain tumor cell types and play a key role in tumor progression and survival.

Clinical Trials

View Clinical Trials for bnz-1

Bnz-1 has been investigated in 1 clinical trial, of which 0 are open and 1 is closed. Of the trial investigating bnz-1, 1 is phase 1/phase 2 (0 open).

Primary cutaneous T-cell non-hodgkin lymphoma, sezary syndrome, and T-cell large granular lymphocyte leukemia are the most common diseases being investigated in bnz-1 clinical trials [2].

Drug Details

Synonyms [2]:
il-2/9/15 gamma chain receptor inhibitor bnz-1, bnz132-1-40
NCIT ID [1]:
C146636

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.